Paper41219185
Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status.
Bian Y and 15 others. Nat Commun, 2025. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status. Papers, record 41219185. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41219185
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ferroptosis | Major topic |
| Proto-Oncogene Proteins p21(ras) | Major topic |
| Polyamines | Major topic |
| Kelch-Like ECH-Associated Protein 1 | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Cell Line, Tumor | |
| Xenograft Model Antitumor Assays | |
| NF-E2-Related Factor 2 | |
| Drug Resistance, Neoplasm | |
| Mutation | |
| Molecular Targeted Therapy |
Source PubMed
References82
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38217522 | Cellular metabolism: A key player in cancer ferroptosis. | Cancer Commun (Lond) | 2024 | https://conductscience.org/library/papers/38217522 | PubMed |
| 2 | 33820777 | Mechanisms of Resistance to KRASG12C-Targeted Therapy. | Cancer Discov | 2021 | https://conductscience.org/library/papers/33820777 | PubMed |
| 3 | 39121480 | Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers. | Cancer Discov | 2024 | https://conductscience.org/library/papers/39121480 | PubMed |
| 4 | 37184371 | Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells. | Cancer Res | 2023 | https://conductscience.org/library/papers/37184371 | PubMed |
| 5 | 33870211 | The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. | Nat Cancer | 2021 | https://conductscience.org/library/papers/33870211 | PubMed |
| 6 | 8500690 | Spermidine/spermine N1-acetyltransferase--the turning point in polyamine metabolism. | FASEB J | 1993 | https://conductscience.org/library/papers/8500690 | PubMed |
| 7 | 9852135 | The identification of a cis-element and a trans-acting factor involved in the response to polyamines and polyamine analogues in the regulation of the human spermidine/spermine N1-acetyltransferase gene transcription. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9852135 | PubMed |
| 8 | 29577948 | l-Arginine induces antioxidant response to prevent oxidative stress via stimulation of glutathione synthesis and activation of Nrf2 pathway. | Food Chem Toxicol | 2018 | https://conductscience.org/library/papers/29577948 | PubMed |
| 9 | 26403645 | Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. | Hepatology | 2016 | https://conductscience.org/library/papers/26403645 | PubMed |
| 10 | 24066166 | Insight into the intermolecular recognition mechanism between Keap1 and IKKβ combining homology modelling, protein-protein docking, molecular dynamics simulations and virtual alanine mutation. | PLoS One | 2013 | https://conductscience.org/library/papers/24066166 | PubMed |
| 11 | 22239440 | Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. | Expert Opin Ther Targets | 2012 | https://conductscience.org/library/papers/22239440 | PubMed |
| 12 | 39317105 | Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis. | Redox Biol | 2024 | https://conductscience.org/library/papers/39317105 | PubMed |
| 13 | 36657446 | Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. | Cell Rep Med | 2023 | https://conductscience.org/library/papers/36657446 | PubMed |
| 14 | 35922812 | Targeting KRAS mutant cancers: from druggable therapy to drug resistance. | Mol Cancer | 2022 | https://conductscience.org/library/papers/35922812 | PubMed |
| 15 | 27698118 | Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. | Proc Natl Acad Sci U S A | 2016 | https://conductscience.org/library/papers/27698118 | PubMed |
| 16 | 18241672 | Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer. | Clin Biochem | 2008 | https://conductscience.org/library/papers/18241672 | PubMed |
| 17 | 24142871 | The emerging role of the Nrf2-Keap1 signaling pathway in cancer. | Genes Dev | 2013 | https://conductscience.org/library/papers/24142871 | PubMed |
| 18 | 25814555 | Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis. | Mol Syst Biol | 2015 | https://conductscience.org/library/papers/25814555 | PubMed |
| 19 | 32955176 | KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32955176 | PubMed |
| 20 | 36707233 | Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. | Gut | 2023 | https://conductscience.org/library/papers/36707233 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42935189 | [From driver gene mutations to cell death crosstalk: Ferroptosis regulatory networks and prospects for targeted cancer therapy]. | Zhong Nan Da Xue Xue Bao Yi Xue Ban | 2026 | https://conductscience.org/library/papers/42935189 | PubMed |
| 42919317 | ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42919317 | PubMed |
| 42866008 | Palmatine Induces TNNT1 Ubiquitination and Degradation to Potentiate Ferroptosis Sensitivity in Hepatocellular Carcinoma. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/42866008 | PubMed |
| 42855676 | Polyamine metabolism in ischemia reperfusion injury: common mitochondrial mechanisms and organ-specific differences. | J Transl Med | 2026 | https://conductscience.org/library/papers/42855676 | PubMed |
| 42757463 | Arginine metabolism, polyamine homeostasis and ferroptosis in cancer: Molecular links and therapeutic opportunities (Review). | Mol Med Rep | 2026 | https://conductscience.org/library/papers/42757463 | PubMed |
| 42630362 | Gene signatures of palmitoylation and fatty acid metabolism predict prognosis and immunotherapy response in breast cancer patients by machine learning, single-cell analysis, and experimental validation. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42630362 | PubMed |
| 42610639 | Carrier-Free Berberine/Nitidine Chloride Self-Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42610639 | PubMed |
| 42099806 | Iron: Regulation, redox homeostasis, and ferroptosis in cancer. | Ferroptosis Oxid Stress | 2026 | https://conductscience.org/library/papers/42099806 | PubMed |
| 42009648 | Unveiling DEFB1 as a novel driver and promising therapeutic target in lung adenocarcinoma. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42009648 | PubMed |
| 41998662 | MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis. | Respir Res | 2026 | https://conductscience.org/library/papers/41998662 | PubMed |
| 41735603 | Translating ferroptosis into oncology: challenges, opportunities and future directions. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/41735603 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| JUN | 3725 | PubTator's text mining | https://conductscience.org/library/genes/3725 | NCBI Gene |
| KEAP1 | 9817 | PubTator's text mining | https://conductscience.org/library/genes/9817 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MAPK8 | 5599 | PubTator's text mining | https://conductscience.org/library/genes/5599 | NCBI Gene |
| NFE2L2 | 4780 | PubTator's text mining | https://conductscience.org/library/genes/4780 | NCBI Gene |
| SAT1 | 6303 | PubTator's text mining | https://conductscience.org/library/genes/6303 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41219185
GET https://conductscience.org/api/papers/v1/41219185/references?page=2